Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 18

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 18
---
 of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S.tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the “IRS”), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S.Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. This discussion is limited to Non-U.S.Holders that hold our common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S.Holder’s particular circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax. In addition, it does not address consequences relevant to Non-U.S.Holders subject to special rules, including, without limitation:

| • |     | U.S. expatriates and former citizens or long-term residents of the United States; |

| • |     | persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a 
 conversion transaction or other integrated investment;                                                         |

| • |     | banks, insurance companies, and other financial institutions; |

| • |     | brokers, dealers or traders in securities; |

| • |     | “controlled foreign corporations,” “passive foreign investment companies” and 
 corporations that accumulate earnings to avoid U.S. federal income tax;       |

| • |     | partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and 
 investors therein);                                                                                              |

| • |     | tax-exempt organizations or governmental organizations; |

| • |     | persons